Overview
Lobbying Costs
1,750,000€ - 1,999,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
4.95 Fte (21)
Lobbyists with EP accreditation
3
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
F. Hoffmann-La Roche Ltd (Roche)
EU Transparency Register
18940431725-51 First registered on 20 May 2009
Goals / Remit
Roche is a pioneer in pharmaceuticals and diagnostics making it a leader in personalised healthcare to advance science. Roche is the world’s largest biotech company, as well as the global leader in in-vitro and tissue-based cancer diagnostics. Since 1896, Roche searches for better ways to prevent, diagnose, and treat diseases and improves patient access to innovation. More than 30 medicines developed by Roche are included in the WHO Model Lists of Essential Medicines. For the 15th consecutive year, Roche was ranked one of the most sustainable companies by the Dow Jones Sustainability Indices. Roche employs over 103,000 people in over 100 countries. In 2023, Roche invested CHF 13.2 billion in R&D and posted sales of CHF 58.7 billion. Genentech, Flatiron Health, and Spark Therapeutics, all based in the US, are wholly owned members of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Main EU files targeted
Our objective is to improve patient safety and strengthen disease prevention in Europe, to provide coverage and reimbursement that reward innovation, and to increase Europe's competitiveness as a location for Research and Development investment. Our interactions with EU Institutions relate to the legislation and implementation of EU regulation at national level, e.g. Access to Medicines, EU Pharmaceutical Strategy, Incentives, Health Technology Assessment, In-Vitro Diagnostic / Medical Devices Regulations, General Data Protection Regulation, Shaping Europe’s Digital Strategy, Horizon Europe, Pharmaceuticals in the Environment, Shortages, Orphan Medicinal Products / Pediatric Regulations, European Green Deal, Cross-border Healthcare, European Health Union. Our expertise and knowledge enables us to contribute convincing arguments on policy topics that are of high priority to us, such as: How to provide patients with timely and safe access to medicines and diagnostics? How to create a culture which fosters innovation, e.g. by granting intellectual property (IP) protection? How to get a fair value for innovative products, devices and services? How to develop innovative diabetes technologies and services for patients? How to use innovative approaches to personalised healthcare by making use of big data while protecting data privacy? Consequently, we provide input to EU Institutions’ open consultations and participate in events sponsored by EU Institutions.
Address
Head Office
Grenzacherstrasse 124
Basel 4070
SWITZERLANDEU Office
Rue Dante 75
Brussels 1070
BELGIUMWebsite
-
People
Total lobbyists declared
21
Employment time Lobbyists 100% 1 50% 3 25% 5 10% 12 Lobbyists (Full time equivalent)
4.95
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
3 accreditations were / are live (in bold) for the selected state of 17 Dec 2024
Name Start date End Date Ludovic LACAINE 20 May 2024 19 May 2026 Peter Bezzegh 10 Jun 2024 31 Dec 2024 Ludovic LACAINE 11 May 2023 11 May 2024 Luc Etienne FAUQUEX 11 May 2023 11 May 2024 Luc-Etienne Fauquex 24 Apr 2024 23 Apr 2026 Ms Nathalie STIEGER 15 Aug 2019 01 Sep 2020 Ms Nathalie STIEGER 06 Sep 2017 02 Sep 2018 Ms Nathalie STIEGER 22 Aug 2016 05 Aug 2017 Ms Christiane Landsberg 29 Jul 2015 28 Jul 2016 Ms Nathalie STIEGER 21 Jun 2015 18 Jun 2016 Ms Nathalie STIEGER 19 Jun 2014 17 Jun 2015 Ms Sabine Atzor 06 Aug 2014 04 Aug 2015 Mrs Sabine Atzor 06 Aug 2014 27 Jan 2015 Mrs Nathalie STIEGER 19 Jun 2014 27 Jan 2015 Mrs Sabine Atzor 09 Aug 2013 06 Aug 2014 Mrs Nathalie STIEGER 16 Apr 2013 11 Apr 2014 Mrs Nathalie STIEGER 10 Feb 2012 01 Mar 2013 Complementary Information
Due to the complexity and highly technical nature of legislations on pharmaceuticals and diagnostics, Roche's approach to EU-related activities is decentralised and aims to mobilise subject-matter experts at the right time for the right issue. This division of tasks takes place based on specific functional expertise. Most experts, mainly located in Roche's headquarters in Basel, Switzerland, only spend a limited amount of their working time on EU-related activities. One person is fully dedicated to EU affairs and works in Brussels.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Roche is a member of the European Federation of Pharmaceutical Industries and Associations EFPIA, MedTech Europe, DigitalEurope, and of national pharmaceutical and diagnostics associations. In addition, Roche is a partner of the European Brain Council EBC, the European Cancer Organisation ECO, IMI’s European Patients' Academy on Therapeutic Innovation EUPATI, the European Organisation for Rare Diseases EURORDIS, the European Round Table for Industry ERT, European Patient Forum EPF, the Project Alzheimers Value Europe (PAVE), EUCOPE, and the European Policy Centre.
Member organisations
Genentech, Flatiron Health, and Spark Therapeutics are wholly owned member of the Roche Group. According to the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, the information published in the present registration also includes their activities.
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
1,750,000€ - 1,999,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount sfl regulatory affairs & scientific communication 100,000€ - 199,999€ acumen public affairs 50,000€ - 99,999€ fti consulting 50,000€ - 99,999€ arc bio communications 50,000€ - 99,999€ evoke incisive health 50,000€ - 99,999€ fipra international 10,000€ - 24,999€ Intermediaries for current year
Name sfl regulatory affairs & scientific communication fipra international evoke incisive health arc bio communications fti consulting acumen public affairs Closed year Costs
1,750,000€ - 1,999,999€
Other financial info
Roche's entries have been made in line with the greatest possible transparency and are periodically being updated as required. The estimates for this update have been done following the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, and are consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
We work actively on communication activities for better health care and access to patients, for instance via the Transforming Breast Cancer Together Initiative (https://www.tbct.eu/). We also advocate for regulatory reforms, such as the Six Bold Actions (https://www.roche.com/stories/roche-in-europe-hub). To this end, we communicate our proposals through publications, social media campaigns, events, or further types of activities. We also contribute to communication activities organized by associations such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), MedTech Europe, the European Brain Council (EBC), the European Cancer Organisation (ECO), the European Patient’s Forum (EPF), the European Organisation for Rare Diseases (EURORDIS), and DigitalEurope.
Other activities
None declared
Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 15 Apr 2024 Location Brussels Subject Meeting WEF CEO Action Group for the European Green Deal Cabinet Cabinet of Vice-President Maroš Šefčovič Attending - Virginie Battu-henriksson (Cabinet member)
- Maroš Šefčovič (Executive Vice-President)
Other Lobbyists -
Date 18 Jan 2023 Location Davos, Switzerland Subject EU Innovation Agenda Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 18 Jan 2023 Location Davos, Switzerland Subject EU Innovation Agenda Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)
-
Date 12 Jul 2022 Location video-call Subject Pharmaceutical directive Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
-
Date 13 Oct 2017 Location Mannheim Subject digital policy Cabinet Cabinet of Vice-President Günther Oettinger Portfolio Budget & Human Resources Attending - Günther Oettinger (Commissioner)